Related Experiment Videos
[Intravitreal bevacizumab for chronic central serous chorioretinopathy]
M F Niegel1, N F Schrage, S Christmann
1Augenklinik, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51109, Köln, Germany. niegelm@kliniken-koeln.de
Abstract:
Central serous chorioretinopathy (CSCR) can lead to permanent visual loss in chronic cases. We report on a 57-year-old female patient with persistent findings over 6 months despite conservative therapy. A single intravitreal injection of bevacizumab led to a rapid morphologic and functional restitution without relapse or complication during the 19 weeks period after injection. Intravitreal injection of bevacizumab could be a therapeutic option for the treatment of chronic CSCR, however the results of appropriate studies must be awaited before it can be introduced into routine use.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy
Glaucoma: Overview